ABSTRACT
Objective: The aim of this study was to evaluate the impact of Holder pasteurization on total microRNA (miRNA) levels in donor human milk, comparing paired samples before and after pasteurization, with freshly expressed human milk included as a contextual reference.
Methods: This longitudinal exploratory study included 17 lactating women. Donor human milk samples (n=10) were collected at the Human Milk Bank and analyzed immediately before and after Holder pasteurization (62.5°C for 30 minutes). Freshly expressed samples (n=7), from postpartum and Kangaroo Method mothers, were analyzed shortly after expression as a contextual reference. Total miRNAs were extracted and quantified by spectrophotometry (NanoDrop) and fluorometry (Qubit). Paired comparisons used the Wilcoxon signed-rank test; contextual comparisons across milk groups used the Kruskal-Wallis test.
Results: Holder pasteurization was associated with a significant reduction in total miRNA levels in donor human milk. Fluorometric quantification showed a decrease in median concentration from 19.9 ng/μL (interquartile range [IQR]: 7.2–45.8) before pasteurization to 4.8 ng/μL (2.6–10.2) after pasteurization (p=0.005). Similar findings were observed by spectrophotometry, with median concentrations decreasing from 35.1 ng/μL (21.4–58.2) to 3.8 ng/μL (1.6–6.5) (p=0.005). Freshly expressed milk showed higher miRNA concentrations than donor milk samples.
Conclusions: Holder pasteurization was associated with a marked reduction in total miRNA levels in donor human milk, suggesting an influence of thermal processing on bioactive milk components. Nevertheless, pasteurized donor human milk remains the safest and most recommended alternative when a mother's own milk is unavailable, particularly for preterm infants.
Keywords:
Human milk; MicroRNAs; Pasteurization; Human milk banks; Donor milk
RESUMO
Objetivo: Avaliar o impacto da pasteurização Holder sobre os níveis totais de microRNAs (miRNAs) no leite humano doado, comparando amostras pareadas antes e após a pasteurização, com leite humano recém-extraído incluído como referência contextual.
Métodos: Estudo longitudinal exploratório que incluiu 17 mulheres lactantes. Amostras de leite humano doado (n=10) foram coletadas no Banco de Leite Humano e analisadas imediatamente antes e após a pasteurização Holder (62,5°C por 30 minutos). Amostras de leite recém-extraído (n=7), de puérperas e mães do Método Canguru, foram analisadas logo após a ordenha como referência contextual. Os miRNAs totais foram extraídos e quantificados por espectrofotometria (NanoDrop) e fluorometria (Qubit). Comparações pareadas utilizaram o teste de Wilcoxon; comparações contextuais entre os grupos utilizaram o teste de Kruskal-Wallis.
Resultados: A pasteurização Holder foi associada a redução significativa dos níveis totais de miRNAs no leite doado. A fluorometria mostrou redução da mediana de 19,9 ng/μL (IIQ: 7,2–45,8) antes para 4,8 ng/μL (2,6–10,2) após a pasteurização (p=0,005). Achados semelhantes foram observados por espectrofotometria, com redução das medianas de 35,1 ng/μL (21,4–58,2) para 3,8 ng/μL (1,6–6,5) (p=0,005). O leite recém-extraído apresentou concentrações de miRNAs mais elevadas que o leite doado.
Conclusões: A pasteurização Holder foi associada a redução expressiva dos níveis totais de miRNAs no leite doado, sugerindo influência do processamento térmico sobre componentes bioativos do leite. Entretanto, o leite doado pasteurizado permanece a alternativa mais segura e recomendada quando o leite da própria mãe não está disponível, especialmente para prematuros.
Palavras-chave:
Leite humano; MicroRNAs; Pasteurização; Bancos de leite humano; Leite doado
INTRODUCTION
Breastfeeding is a key intervention for maternal and child health. The World Health Organization recommends exclusive breastfeeding for the first 6 months and continued breastfeeding for 2 years or more.1 It reduces infant mortality and infectious diseases and is associated with long-term protection against obesity, diabetes, allergic conditions, and adverse neurodevelopmental outcomes.2,3 These benefits are particularly relevant for preterm newborns, who often require prolonged hospitalization and face multiple complications. In this population, mothers’ own milk is the preferred feeding option; when unavailable, pasteurized donor human milk from human milk banks (HMBs) is the recommended alternative.4–6 Although pasteurization preserves many protective properties and is associated with lower morbidity than formula—especially reduced necrotizing enterocolitis7 — it may affect thermosensitive bioactive components.8 Among the available thermal methods, Holder pasteurization (62.5°C for 30 minutes) is the most widely used and recommended technique in HMBs worldwide, as it effectively ensures microbiological safety while preserving many of the biological properties of donor human milk, which justifies its selection as the processing method evaluated in the present study.4–6
Human milk is a complex and dynamic biological fluid that provides not only nutrients but also cells, microorganisms, and bioactive molecules that modulate immunological, metabolic, and molecular processes.9 Among these, microRNAs (miRNAs) have gained increasing attention due to their role in the epigenetic regulation of gene expression and potential influence on postnatal development.10 Most miRNAs are encapsulated within extracellular vesicles, such as exosomes and microvesicles, thereby enhancing their stability and protecting them from degradation. Derived predominantly from mammary epithelial cells, these molecules are involved in pathways related to inflammation, angiogenesis, metabolism, immune regulation, and neuroprotection. Highly abundant miRNAs in human milk — including miR-148a-3p, miR-30a/d-5p, members of the let-7 family, and miR-146b-5p — have been associated with infant growth and metabolic, immunological, and neurological development.11,12
Although miRNAs in human milk appear relatively stable under conditions such as pH variation, digestion, freezing, and freeze-thaw cycles, their response to thermal processing remains unclear, with limited and sometimes inconsistent evidence.13–15 Pasteurized donor human milk is widely used in neonatal care, particularly for preterm infants; however, the effects of Holder pasteurization on miRNA levels remain insufficiently characterized.
This study aimed to evaluate the impact of Holder pasteurization on miRNA levels by comparing paired donor human milk samples before and after pasteurization. Freshly expressed human milk analyzed shortly after expression was additionally included as a contextual reference.
METHOD
This longitudinal study was conducted between March and July 2025 and followed the STROBE statement. The study population included lactating women registered as human milk donors at the HMB (n=10), whose milk samples were analyzed before and after pasteurization, as well as lactating mothers providing fresh milk samples (n=7), including postpartum women in rooming-in care (n=2) and mothers participating in the Kangaroo Method whose newborns were either hospitalized or undergoing outpatient follow-up (n=5). Eligible participants were invited to take part in the study during routine care at the HMB, in hospital inpatient units (maternity ward or neonatal intensive care unit), and at the Kangaroo outpatient clinic.
Due to the exploratory nature of the study and the limited availability of eligible participants during the study period, a convenience sample was adopted, and no formal sample size calculation was performed.
Mothers with rheumatic, hepatic, renal, cardiac, or infectious diseases, or those using immunosuppressive drugs that are totally or partially contraindicated for breastfeeding, were excluded. A standardized questionnaire was used to collect information on maternal age, date of delivery, medical and obstetric history, gestational age, and newborn sex.
The primary analysis of the study evaluated the effect of Holder pasteurization on miRNA levels through paired comparisons of donor human milk samples collected immediately before and after pasteurization. Freshly expressed human milk samples were additionally included as a contextual reference group. Because donor milk had already undergone freezing, storage, and transport before pasteurization, the comparison between fresh milk and donor milk before pasteurization reflects differences related mainly to storage and handling — particularly freezing — rather than thermal treatment itself, which is addressed separately by the paired before/after pasteurization comparison.
Human milk from donor mothers was obtained by manual expression or breast pump at home, stored in glass bottles with plastic screw caps, and kept in a domestic freezer (-20°C) for up to 7 days, in accordance with standard HMB guidelines. The bottles were transported under refrigeration to the HMB, where they were thawed and pasteurized according to the institutional protocol. From each bottle, paired aliquots of 5–10 mL were collected immediately before and after pasteurization, allowing intra-sample comparisons for quantitative miRNA analysis.
In postpartum and Kangaroo women, 5–10 mL of human milk was collected by manual expression before breastfeeding. These samples were immediately transported under refrigeration, aliquoted, and submitted to microRNA extraction and quantification within 6 hours of expression. All samples were stored and processed at the Molecular Biology Laboratory in accordance with standard laboratory protocols.
Human milk pasteurization was performed at the HMB using the Holder method, in accordance with current technical standards.16,17 After controlled thawing, the samples were transferred to labeled glass bottles and placed in a thermostatically controlled water bath at 62.5°C for 30 minutes, with continuous temperature monitoring using a calibrated thermometer. At the end of the heating period, the bottles were immediately cooled in a cold-water bath to below 10°C and subsequently stored in accordance with routine HMB procedures. Aliquots for the study were collected immediately after pasteurization, before any additional storage or freezing cycles.
All laboratory procedures were carried out at the Molecular Biology Laboratory. Prior to extraction, human milk samples were homogenized in 800 μL of lysis buffer prepared on the day of the experiment, composed of 100 mM Tris (hydroxymethyl) aminomethane (Tris) base (pH 7.5), 20 mM ethylenediaminetetraacetic acid (EDTA), 100 mM sodium fluoride, 100 mM sodium pyrophosphate, 10 mM sodium orthovanadate, 2 mM phenylmethylsulfonyl fluoride (PMSF), and 2 mg/mL aprotinin, in order to obtain total extracts and preserve nucleic acid integrity.
Total RNA, including the miRNA fraction, was extracted using the miRNeasy Mini Kit (Qiagen, Valencia, CA, USA),18 following the manufacturer's instructions. This procedure is based on purification through silica membrane columns, allowing efficient recovery of RNAs of different sizes.
RNA concentration and purity were assessed using two complementary approaches. Spectrophotometric analysis was performed with a NanoDrop ND-1000 (Thermo Fisher Scientific, Waltham, MA, USA), with absorbance readings at 260, 280, and 230 nm, and sample quality was evaluated using the 260/280 nm and 260/230 nm ratios.19,20
Fluorometric quantification was subsequently performed using a Qubit Fluorometer (Thermo Fisher Scientific, Waltham, MA, USA) with an RNA-specific assay, as recommended by the manufacturer, due to its greater sensitivity and specificity for samples with low RNA concentrations and potential interfering substances, such as human milk.21,22 After extraction and quantification, the miRNA samples were stored at −80 °C until further molecular analyses. To minimize measurement bias, all laboratory analyses were performed using standardized procedures and two complementary quantification methods.
The study was approved by the Research Ethics Committee of Centro Universitário FMABC (approval no. 8,267,007; CAAE: 74670723.3.0000.0082). All participants provided written informed consent after receiving detailed information about the study objectives and procedures.
Statistical analysis was performed using IBM SPSS Statistics for Windows (IBM Corp., Armonk, NY, USA), version 29.0, and GraphPad Prism, version 12.1 (GraphPad Software, San Diego, CA, USA). Categorical and dichotomous variables were expressed as absolute numbers and percentages. The distribution of continuous variables was assessed using histograms and kurtosis values. Because the data were not normally distributed, paired comparisons before and after pasteurization were performed using the Wilcoxon signed-rank test. Comparisons between milk groups were conducted using the Kruskal-Wallis test as an exploratory contextual analysis. Statistical significance was defined as p<0.05.
RESULTS
In total, 17 women were included in the study, comprising 10 HMB donors and 7 lactating mothers who provided freshly expressed milk samples. Maternal age ranged from 22 to 40 years, and most infants were born at term. Breastfeeding duration at the time of sample collection ranged from 3 to 365 days. Participant characteristics are presented in Table 1.
The primary analysis evaluated the effect of Holder pasteurization on donor human milk (n=10 paired samples). Pasteurization was associated with a substantial reduction in total miRNA levels. Fluorometric quantification demonstrated a decrease in median concentration from 19.9 ng/μL (interquartile range [IQR]: 7.2–45.8) before pasteurization to 4.8 ng/μL (2.6–10.2) after pasteurization (p=0.005). Similar findings were obtained using spectrophotometry, with median values declining from 35.1 ng/μL (21.4–58.2) to 3.8 ng/μL (1.6–6.5) (p=0.005) (Table 2; Figure 1).
Fluorometric quantification of total miRNA levels in donor human milk before and after Holder pasteurization.
As a contextual comparison, fluorometric quantification showed differences across milk samples obtained under different handling and processing conditions (Figure 2). Freshly expressed human milk analyzed shortly after expression showed higher total miRNA concentrations (median 26.9 ng/μL; IQR: 19.6–46.1), followed by donor milk before pasteurization (median 19.9 ng/μL; IQR: 7.2–45.8), whereas pasteurized donor milk exhibited the lowest levels (median 4.8 ng/μL; IQR: 2.6–10.2) (Kruskal-Wallis H=11.21, p=0.004). Pairwise post-hoc comparisons (Dunn–Bonferroni) showed no significant difference between freshly expressed milk and donor milk before pasteurization (adjusted p=1.000), whereas donor milk after pasteurization differed significantly from both freshly expressed milk (adjusted p=0.008) and donor milk before pasteurization (adjusted p=0.026).
Comparison of total miRNA levels across different human milk handling and processing conditions.
DISCUSSION
The present study demonstrated a significant reduction in total miRNA levels after Holder pasteurization of donor human milk, reinforcing the potential influence of thermal processing on the preservation of bioactive milk components. In addition, freshly expressed human milk analyzed shortly after expression showed higher miRNA concentrations than donor milk samples obtained after storage and processing, suggesting that handling conditions may also contribute to differences in miRNA preservation. Given the growing recognition of miRNAs as bioactive molecules involved in immune, metabolic, and developmental pathways, these findings contribute to the understanding of how milk processing may affect specific biological components of donor human milk.
MicroRNAs in human milk have been proposed as a promising mechanism involved in early biological regulation, although further studies are still needed to clarify their bioavailability, physiological roles, and clinical relevance.11 Most miRNAs are protected within extracellular vesicles, which increase their stability and resistance to degradation. However, previous studies evaluating storage and heating practices for expressed human milk suggest that room temperature exposure, prolonged freezing, and thermal processing may influence miRNA concentrations and alter specific miRNA groups with important biological functions.13–15
In the present study, donor milk samples subjected to routine storage, transport, thawing, and pasteurization showed lower total miRNA concentrations than freshly expressed milk analyzed shortly after expression. Although causal inferences cannot be made regarding the individual contribution of each processing step, these findings suggest that cumulative handling and thermal processing conditions may influence miRNA preservation in donor human milk.
The considerable inter-individual variability observed in baseline miRNA concentrations before pasteurization also deserves consideration. Biological factors such as stage of lactation, maternal characteristics, and overall milk composition are known to influence miRNA content, while methodological factors, including storage conditions prior to analysis and inherent analytical variability of quantification methods, may have further contributed to this heterogeneity. Given the small and clinically heterogeneous sample evaluated here, these sources of variability should be considered when interpreting the magnitude of the observed reduction.
Previous studies have also demonstrated that human milk contains a wide diversity of miRNAs distributed across different milk fractions and that thermal processing may reduce their concentration.13,14 A study comparing Holder pasteurization with ultra-high temperature (UHT) processing reported marked degradation of miRNAs after Holder pasteurization, whereas alternative thermal methods appeared to better preserve overall miRNA content, reinforcing the role of thermal intensity as an important determinant of miRNA preservation.13 Together, these findings support the hypothesis that thermal processing may substantially affect bioactive components of donor human milk.
A scoping review on miRNAs in human milk similarly highlighted that processing conditions, including thermal treatment, may alter miRNA profiles, although the number of studies directly addressing Holder pasteurization remains limited.14 Likewise, changes in miRNA content have been reported across storage and processing steps commonly applied to expressed human milk, reinforcing that handling conditions beyond pasteurization itself may also contribute to quantitative variability.15,23 It should be acknowledged that comparable studies specifically evaluating Holder pasteurization and miRNA content remain scarce, which limits broader contextualization of the present findings.
Holder pasteurization is the standard method adopted by HMBs because it reliably eliminates pathogenic microorganisms while preserving many of the nutritional and immunological properties of donor human milk, making it the safest available option for infants who depend on banked milk. Understanding its impact on miRNA preservation is therefore clinically relevant, as these molecules are increasingly recognized as bioactive regulators of infant immune, metabolic, and neurological development, and any processing-related loss could have downstream implications for the functional quality of donor milk. Despite these findings, pasteurized donor human milk remains the safest and most recommended alternative when a mother's own milk is unavailable, particularly for preterm infants. Donor human milk has consistently been associated with lower morbidity than infant formula, especially a reduced risk of necrotizing enterocolitis.24 Furthermore, studies comparing human milk and infant formula have demonstrated markedly lower miRNA levels in formula, even when compared with pasteurized donor milk.25 Therefore, the biological implications of reduced miRNA levels should be interpreted with caution and should not discourage the use of donor human milk in neonatal care.
These findings also reinforce the importance of strategies aimed at promoting mothers’ own milk and direct breastfeeding whenever possible, particularly among preterm newborns and other vulnerable populations. At the same time, further investigation into processing methods used in HMBs remains important not only to ensure microbiological safety but also to optimize preservation of the functional and regulatory components of human milk. This issue is particularly relevant in Brazil, which has the largest network of HMBs in the world and extensively uses pasteurized donor human milk in neonatal intensive care units.
This study has several strengths. First, it provides a direct paired evaluation of the effect of Holder pasteurization on total miRNA levels in donor human milk using two independent quantification methods, increasing the reliability of the findings. In addition, the detailed description of milk handling, transport, and processing procedures improves methodological reproducibility and facilitates comparison with other studies.
Some limitations should be acknowledged. First, this exploratory study included a small convenience sample without formal sample size calculation, which limits statistical power and external validity. Second, the sample was heterogeneous, including donor milk and freshly expressed milk obtained under different clinical conditions, although fresh milk was included only as a contextual reference, which may limit direct comparability and generalizability of the findings. Third, the analysis was restricted to quantitative assessment of total miRNA levels, without characterization of specific miRNA species or functional analyses, limiting conclusions regarding biological mechanisms and clinical implications. Therefore, the results presented here should be interpreted with caution.
In conclusion, Holder pasteurization was associated with a marked reduction in total miRNA levels in donor human milk, reinforcing the potential influence of thermal processing on the preservation of bioactive milk components. Freshly expressed human milk analyzed shortly after expression showed higher miRNA concentrations than donor milk samples subjected to routine handling and processing, suggesting that cumulative processing conditions may also contribute to quantitative differences. Nevertheless, pasteurized donor human milk remains the safest and most recommended alternative when a mother's own milk is unavailable, particularly for preterm infants. Further studies are needed to better characterize the biological and clinical implications of miRNA reduction and to optimize HMB processing strategies while preserving microbiological safety.
Funding
Registration
Data availability statement
The database that gave rise to the article is available upon request from the corresponding author.
REFERENCES
- 1 World Health Organization. WHO guideline for complementary feeding of infants and young children 6–23 months of age. Geneva: World Health Organization; 2023.
-
2 Victora CG, Bahl R, Barros AJ, França GV, Horton S, Krasevec J, et al. Breastfeeding in the 21st century: epidemiology, mechanisms, and lifelong effect. Lancet. 2016;387:475-90. https://doi.org/10.1016/S0140-6736(15)01024-7
» https://doi.org/10.1016/S0140-6736(15)01024-7 -
3 Strobel NA, Adams C, McAullay DR, Edmond KM. Mother's own milk compared with formula milk for feeding preterm or low birth weight infants: systematic review and meta-analysis. Pediatrics. 2022;150(Suppl 1):e2022057092D. https://doi.org/10.1542/peds.2022-057092D
» https://doi.org/10.1542/peds.2022-057092D -
4 Quigley M, Embleton ND, McGuire W. Formula versus donor breast milk for feeding preterm or low birth weight infants. Cochrane Database Syst Rev. 2019;7:CD002971. https://doi.org/10.1002/14651858.CD002971.pub5
» https://doi.org/10.1002/14651858.CD002971.pub5 -
5 Modi N. Human milk for preterm infants. Semin Fetal Neonatal Med. 2025;30:101634. https://doi.org/10.1016/j.siny.2025.101634
» https://doi.org/10.1016/j.siny.2025.101634 -
6 Liu C, Pan M, Lu X, Gao Y, Xu J, Chen X. Breastfeeding barriers for preterm infants in neonatal intensive care unit environments: a systematic assessment and meta-analysis. Breastfeed Med. 2024;19:505-14. https://doi.org/10.1089/bfm.2024.0041
» https://doi.org/10.1089/bfm.2024.0041 -
7 Underwood MA. The fifty billion dollar question: does formula cause necrotising enterocolitis? J Perinatol. 2025;45:565-71. https://doi.org/10.1038/s41372-025-02277-2
» https://doi.org/10.1038/s41372-025-02277-2 -
8 Rosenblum N, McAlduff N, Lowe V. The financial feasibility for providing expanded access to donor milk for low-risk preterm and full-term newborn infants: an integrative review. Breastfeed Med. 2025. https://doi.org/10.1177/15568253251389960 Online ahead of print.
» https://doi.org/10.1177/15568253251389960 -
9 Donovan SM, Aghaeepour N, Andres A, Azad MB, Becker M, Carlson SE, et al. Evidence for human milk as a biological system and recommendations for study design: a report from the Breastmilk Ecology: Genesis of Infant Nutrition ( ) Working Group 4. Am J Clin Nutr. 2023;117 Suppl 1:S61-86. https://doi.org/10.1016/j.ajcnut.2022.12.021
» https://doi.org/10.1016/j.ajcnut.2022.12.021 -
10 Hatmal MM, Al-Hatamleh MA, Olaimat AN, Alshaer W, Hasan H, Albakri KA, et al. Immunomodulatory properties of human breast milk: microRNA contents and potential epigenetic effects. Biomedicines. 2022;10:1219. https://doi.org/10.3390/biomedicines10061219
» https://doi.org/10.3390/biomedicines10061219 -
11 Tingö L, Ahlberg E, Johansson L, Pedersen SA, Chawla K, Sætrom P, et al. Non-coding RNAs in human breast milk: a systematic review. Front Immunol. 2021;12:725323. https://doi.org/10.3389/fimmu.2021.725323
» https://doi.org/10.3389/fimmu.2021.725323 -
12 Hicks SD, Confair A, Warren K, Chandran D. Levels of breast milk microRNAs and other non-coding RNAs are impacted by milk maturity and maternal diet. Front Immunol. 2022;12:785217. https://doi.org/10.3389/fimmu.2021.785217
» https://doi.org/10.3389/fimmu.2021.785217 -
13 Smyczynska U, Bartlomiejczyk MA, Stanczak MM, Sztromwasser P, Wesolowska A, Barbarska O, et al. Impact of processing method on donated human breast milk microRNA content. PLoS One. 2020;15:e0236126. https://doi.org/10.1371/journal.pone.0236126
» https://doi.org/10.1371/journal.pone.0236126 -
14 Kondracka A, Gil-Kulik P, Kondracki B, Frąszczak K, Oniszczuk A, Rybak-Krzyszkowska M, et al. Occurrence, role, and challenges of microRNA in human breast milk: a scoping review. Biomedicines. 2023;11:248. https://doi.org/10.3390/biomedicines11020248
» https://doi.org/10.3390/biomedicines11020248 -
15 Kim JH, Kim KU, Min H, Lee ES, Lim IS, Song J, et al. Changes in microRNAs during storage and processing of breast milk. Metabolites. 2023;13:139. https://doi.org/10.3390/metabo13020139
» https://doi.org/10.3390/metabo13020139 -
16 Moro GE, Billeaud C, Rachel B, Calvo J, Cavallarin L, Christen L, et al. Processing of donor human milk: update and recommendations from the European Milk Bank Association (EMBA). Front Pediatr. 2019;7:49. https://doi.org/10.3389/fped.2019.00049
» https://doi.org/10.3389/fped.2019.00049 - 17 Brasil. Ministério da Saúde. Resolução RDC no 171 de 4 de setembro de 2006. Dispõe sobre o Regulamento Técnico para o funcionamento de Bancos de Leite Humano. Brasília: Diário Oficial da União; 2006.
- 18 Qiagen. miRNeasy Mini Handbook. Hilden: Qiagen; 2012.
-
19 Manchester KL. Use of UV methods for measurement of protein and nucleic acid concentrations. Biotechniques. 1996;20:968-70. https://doi.org/10.2144/96206bm05
» https://doi.org/10.2144/96206bm05 -
20 Desjardins P, Conklin D. NanoDrop microvolume quantitation of nucleic acids. J Vis Exp. 2010;45:2565. https://doi.org/10.3791/256
» https://doi.org/10.3791/256 - 21 Thermo Fisher Scientific. Qubit RNA assay kits user guide. Waltham: Thermo Fisher Scientific; 2015.
-
22 Simbolo M, Gottardi M, Corbo V, Fassan M, Mafficini A, Malpeli G, et al. DNA qualification workflow for next generation sequencing of histopathological samples. PLoS One. 2013;8:e62692. https://doi.org/10.1371/journal.pone.0062692
» https://doi.org/10.1371/journal.pone.0062692 -
23 Wang H, Wu D, Sukreet S, Delaney A, Belfort MB, Zempleni J. Quantitation of exosomes and their microRNA cargos in frozen human milk. JPGN Rep. 2022;3:e172. https://doi.org/10.1097/pg9.0000000000000172
» https://doi.org/10.1097/pg9.0000000000000172 -
24 Quigley M, Embleton ND, Meader N, McGuire W. Donor human milk for preventing necrotising enterocolitis in very preterm or very low-birthweight infants. Cochrane Database Syst Rev. 2024;9:CD002971. https://doi.org/10.1002/14651858.CD002971.pub6
» https://doi.org/10.1002/14651858.CD002971.pub6 -
25 Chiba T, Kooka A, Kowatari K, Yoshizawa M, Chiba N, Takaguri A, et al. Expression profiles of hsa-miR-148a-3p and hsa-miR-125b-5p in human breast milk and infant formulae. Int Breastfeed J. 2022;17:1. https://doi.org/10.1186/s13006-021-00436-7
» https://doi.org/10.1186/s13006-021-00436-7



Wilcoxon signed-rank test (p=0.005).Source: Data from the present study.
Kruskal-Wallis test, H=11.21, p=0.004.A) Fresh milk, B) donor milk (before pasteurization), and C) donor milk (after pasteurization).Dunn-Bonferroni pairwise comparisons: A vs. B, adjusted p=1.000 (ns); A vs. C, adjusted p=0.008; B vs. C, adjusted p=0.026.Source: Data from the present study.